Akebia Therapeutics shares rose after forecasting significant 2026 revenue growth for its anemia drug Vafseo. The company expects gains from dialysis access and new patient starts. Akebia also plans to start mid-stage trials for AKB-097 in rare kidney diseases in late 2026, holding $184.8 million in cash to fund operations.